Fiber fix? inulin may supercharge GLP-1 Weight-Loss drugs for heart health

NCT ID NCT07611552

Not yet recruiting Disease control Sponsor: Huazhong University of Science and Technology Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether taking inulin, a type of dietary fiber, can improve cholesterol and other heart-related risk factors in 600 overweight or obese adults who are already using GLP-1 medications (like semaglutide) for weight loss. Participants will take either 10 grams of inulin or a placebo daily for 4 months. The goal is to see if adding this simple supplement can make these popular weight-loss drugs even better for long-term heart health.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: inulin (a type of dietary fiber/prebiotic)
What this could lead to: If it works, adding inulin to GLP-1 medications could improve cholesterol and triglyceride levels, making weight-loss treatments better for heart health.
What could go wrong: This is an early-stage supplement study, not a drug trial. The effect may be small or not noticeable, and gastrointestinal side effects like diarrhea or constipation are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY & OVERWEIGHT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight Weight Loss

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY & OVERWEIGHT

Contacts and locations

Locations

Huazhong University of Science and Technology

Wuhan, Hubei, China
Sinopharm Dongfeng General Hospital

Shiyan, Hubei, China
The Central Hospital of Enshi Tujia and Miao Autonomous Prefecture

Enshi, Hubei, China
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Wuhan, Hubei, China
Xiangyang No.1 People's Hospital

Xiangyang, Hubei, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.